Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting ...

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case May 04, 2025 4:17 PM ET Arvinas, Inc. (ARVN) Stock ARVN 3 Comments 1 Like Edward Vranic, CFA 6.6K Follower s ...

Barclays analyst Peter Lawson maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $48.00. The company’s shares closed yesterday at $19.74.